New drug xaluritamig takes on tough ewing sarcoma in early trial
NCT ID NCT07297979
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a drug called xaluritamig (AMG 509) in 50 adults, adolescents, and children with Ewing sarcoma that has relapsed or not responded to prior treatments. The main goals are to find a safe dose and check for side effects. Researchers will also measure how the drug moves through the body and look for any signs that it is fighting the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
xaluritamig (AMG 509), a drug given by IV infusion
What this could lead to
If it works, this could point toward a new treatment option for people with Ewing sarcoma that has come back or not responded to standard therapy.
What could go wrong
This is a very early (phase 1b) and small trial (50 people), so it may not show enough benefit or could have side effects. Success is far from guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars Sinai Medical Center
RECRUITINGLos Angeles, California, 90048, United States
-
Chris OBrien Lifehouse
RECRUITINGCamperdown, New South Wales, 2050, Australia
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
Perth Childrens Hospital
RECRUITINGNedlands, Western Australia, 6009, Australia
-
Peter MacCallum Cancer Centre
RECRUITINGMelbourne, Victoria, 3000, Australia
-
University of California Los Angeles
RECRUITINGLos Angeles, California, 90995-1752, United States